INBX
Inhibrx Biosciences, Inc.
November 3, 2026 · intraday
- Rarity
- 1.60
- Peak move
- +15.03%
- Float cap
- $736M
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapeutics using its modular protein engineering platforms. Its lead candidates include ozekibart, a tetravalent DR5 agonist for solid tumors such as chondrosarcoma and colorectal cancer, and INBRX-106, a hexavalent OX40 agonist for non-small cell lung cancer and head and neck squamous cell carcinoma. The company targets challenging validated pathways to address high unmet medical need in oncology.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.